"Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023" Published

From: Fast Market Research, Inc.
Published: Tue Jun 17 2014


Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Pristiq (desvenlafaxine) is an SNRI antidepressant that was developed by Wyeth, before Wyeth was acquired by Pfizer. Pristiq was launched in the US and Australia in 2008, but is not available in the 5EU and Japan. Pristiq is closely related to Effexor, and more specifically, is the major active metabolite of Effexor. Therefore, despite being a newer SNRI antidepressant, Pristiq will be unable to match the success of Cymbalta and Effexor. Preclinical studies have shown that Pristiq is a potent SNRI, which is believed to cause its antidepressant effects.

Full Report Details at
- http://www.fastmr.com/prod/837502_pristiq_major_depressive_disorder_forecast_and.aspx?afid=302

Scope

* Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Pristiq including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Pristiq for the top three countries from 2013 to 2023.
* Sales information covered for the US, Spain and Australia.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Pristiq performance
* Obtain sales forecast for Pristiq from 2013-2023 in the top three countries (the US, Spain and Australia)

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023
- PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
- Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »